{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:36:13Z","timestamp":1787070973920,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Gastric cancer is a common cause of cancer-related death worldwide, and peritoneal dissemination is the most frequent metastatic pattern of gastric cancer. However, the treatment of this disease condition remains difficult. It has been demonstrated that intraperitoneal radioimmunotherapy (ipRIT) with\n                      <jats:sup>64<\/jats:sup>\n                      Cu-labeled cetuximab (anti-epidermal growth factor receptor antibody;\n                      <jats:sup>64<\/jats:sup>\n                      Cu-cetuximab) is a potential treatment for peritoneal dissemination of gastrointestinal cancer\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      . Recent preclinical and clinical studies have also shown that a histone deacetylase inhibitor, vorinostat, effectively sensitized gastrointestinal cancer to external radiation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>\n                      In the present study, we examined the efficacy of the combined use of vorinostat, as a radiosensitizer during ipRIT with\n                      <jats:sup>64<\/jats:sup>\n                      Cu-cetuximab in a peritoneal dissemination mouse model with human gastric cancer NUGC4 cells stably expressing red fluorescent protein.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The mouse model was treated by ipRIT with\n                      <jats:sup>64<\/jats:sup>\n                      Cu-cetuximab plus vorinostat, each single treatment, or saline (control). Side effects, including hematological and biochemical parameters, were evaluated in similarly treated, tumor-free mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Coadministration of ipRIT with\n                      <jats:sup>64<\/jats:sup>\n                      Cu-cetuximab + vorinostat significantly prolonged survival compared to control and each single treatment. No significant toxicity signals were observed in all treatment groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Our data suggest that vorinostat is a potentially effective radiosensitizer for use during the treatment of peritoneal dissemination of gastric cancer by ipRIT with\n                      <jats:sup>64<\/jats:sup>\n                      Cu-cetuximab.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_124_20","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T02:33:28Z","timestamp":1604370808000},"page":"907-914","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of vorinostat-sensitized intraperitoneal radioimmunotherapy with 64Cu-labeled cetuximab against peritoneal dissemination of gastric cancer in a mouse model"],"prefix":"10.4103","volume":"18","author":[{"given":"Tomoko","family":"Tachibana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nagatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukiko","family":"Hihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Sugyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi B.","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20241021","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/CMAR.S149619","article-title":"Gastric cancer: Epidemiology, prevention, classification, and treatment","volume":"10","author":"Sitarz","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R2-6-20241021","first-page":"77","article-title":"Survival of metastatic gastric cancer: Significance of age, sex and race\/ethnicity","volume":"2","author":"Yang","year":"2011","journal-title":"J Gastrointest Oncol"},{"key":"R3-6-20241021","doi-asserted-by":"crossref","first-page":"28935","DOI":"10.18632\/oncotarget.25649","article-title":"Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64 Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts","volume":"9","author":"Yoshii","year":"2018","journal-title":"Oncotarget"},{"key":"R4-6-20241021","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.2967\/jnumed.108.052316","article-title":"Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines","volume":"49","author":"Eiblmaier","year":"2008","journal-title":"J Nucl Med"},{"key":"R5-6-20241021","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nucmedbio.2007.05.010","article-title":"Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule","volume":"34","author":"Nordberg","year":"2007","journal-title":"Nucl Med Biol"},{"key":"R6-6-20241021","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/ijc.25727","article-title":"Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model","volume":"129","author":"Hoeben","year":"2011","journal-title":"Int J Cancer"},{"key":"R7-6-20241021","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2967\/jnumed.111.101857","article-title":"Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks","volume":"54","author":"Saker","year":"2013","journal-title":"J Nucl Med"},{"key":"R8-6-20241021","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/ph7030311","article-title":"Radiolabeled cetuximab conjugates for EGFR targeted cancer diagnostics and therapy","volume":"7","author":"Sihver","year":"2014","journal-title":"Pharmaceuticals (Basel"},{"key":"R9-6-20241021","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1021\/mp4005047","article-title":"177Lu-labeled antibodies for EGFR-targeted SPECT\/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model","volume":"11","author":"Liu","year":"2014","journal-title":"Mol Pharm"},{"key":"R10-6-20241021","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2967\/jnumed.112.118539","article-title":"The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer","volume":"54","author":"Guo","year":"2013","journal-title":"J Nucl Med"},{"key":"R11-6-20241021","first-page":"158","article-title":"Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors","volume":"23","author":"Ping Li","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"R12-6-20241021","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jrr\/rrv042","article-title":"Validation of 64Cu-ATSM damaging DNA via high-LET Auger electron emission","volume":"56","author":"McMillan","year":"2015","journal-title":"J Radiat Res"},{"key":"R13-6-20241021","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1073\/pnas.98.3.1206","article-title":"Copper-64-diacetyl-bis (N4-methylthiosemicarbazone): An agent for radiotherapy","volume":"98","author":"Lewis","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14-6-20241021","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1535-7163.MCT-18-0667","article-title":"Inhibition of copper transport induces apoptosis in triple-negative breast cancer cells and suppresses tumor angiogenesis","volume":"18","author":"Karginova","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"R15-6-20241021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4161\/cbt.7.1.5130","article-title":"The role of p53 in the trafficking of copper-64 to tumor cell nuclei","volume":"7","author":"Eiblmaier","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"R16-6-20241021","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1074\/jbc.M709463200","article-title":"Novel role of antioxidant-1 (Atox1) as a copper-dependent transcription factor involved in cell proliferation","volume":"283","author":"Itoh","year":"2008","journal-title":"J Biol Chem"},{"key":"R17-6-20241021","first-page":"761","article-title":"Quantitative and histochemical analysis of Cu, Zn, and Fe in spontaneous and induced primary tumors of rats","volume":"21","author":"Arnold","year":"1961","journal-title":"Cancer Res"},{"key":"R18-6-20241021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000226711","article-title":"Localization of tissue copper in mouse mammary tumors","volume":"46","author":"Fuchs","year":"1989","journal-title":"Oncology"},{"key":"R19-6-20241021","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.2741\/1424","article-title":"Copper storage diseases: Menkes, Wilsons, and cancer","volume":"9","author":"Daniel","year":"2004","journal-title":"Front Biosci"},{"key":"R20-6-20241021","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.nucmedbio.2016.07.007","article-title":"Efficient preparation of high-quality 64 Cu for routine use","volume":"43","author":"Ohya","year":"2016","journal-title":"Nucl Med Biol"},{"key":"R21-6-20241021","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1245\/s10434-016-5097-3","article-title":"Effect of EGFR and p-AKT overexpression on chromosomal instability in gastric cancer","volume":"23","author":"Hisamatsu","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R22-6-20241021","first-page":"2727","article-title":"Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis","volume":"18","author":"Slesak","year":"1998","journal-title":"Anticancer Res"},{"key":"R23-6-20241021","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1200\/JCO.2006.07.1316","article-title":"Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127","volume":"24","author":"Dragovich","year":"2006","journal-title":"J Clin Oncol"},{"key":"R24-6-20241021","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.canlet.2011.03.010","article-title":"Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms","volume":"306","author":"Mueller","year":"2011","journal-title":"Cancer Lett"},{"key":"R25-6-20241021","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ijrobp.2009.01.068","article-title":"Radiosensitization by SAHA in experimental colorectal carcinoma models:In vivo effects and relevance of histone acetylation status","volume":"74","author":"Folkvord","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-6-20241021","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/bjc.2013.21","article-title":"Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair","volume":"108","author":"Groselj","year":"2013","journal-title":"Br J Cancer"},{"key":"R27-6-20241021","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1748-717X-7-165","article-title":"Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma","volume":"7","author":"Saelen","year":"2012","journal-title":"Radiat Oncol"},{"key":"R28-6-20241021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1748-717X-6-33","article-title":"Gastrointestinal toxicity of vorinostat: Reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy","volume":"6","author":"Bratland","year":"2011","journal-title":"Radiat Oncol"},{"key":"R29-6-20241021","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1433-2","article-title":"Vorinostat as a radiosensitizer for brain metastasis: A phase I clinical trial","volume":"118","author":"Shi","year":"2014","journal-title":"J Neurooncol"},{"key":"R30-6-20241021","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ajh.23460","article-title":"A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma","volume":"88","author":"Witzig","year":"2013","journal-title":"Am J Hematol"},{"key":"R31-6-20241021","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/10428194.2014.914195","article-title":"Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab","volume":"56","author":"Elstrom","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R32-6-20241021","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2967\/jnumed.115.167155","article-title":"Immuno-PET imaging and radioimmunotherapy of 64Cu-\/177Lu-labeled anti-EGFR antibody in esophageal squamous cell carcinoma model","volume":"57","author":"Song","year":"2016","journal-title":"J Nucl Med"},{"key":"R33-6-20241021","doi-asserted-by":"crossref","first-page":"88815","DOI":"10.18632\/oncotarget.21323","article-title":"64 Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts","volume":"8","author":"Yoshii","year":"2017","journal-title":"Oncotarget"},{"key":"R34-6-20241021","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2967\/jnumed.118.225045","article-title":"64 Cu-Intraperitoneal radioimmunotherapy: A novel approach for adjuvant treatment in a clinically relevant preclinical model of pancreatic cancer","volume":"60","author":"Yoshii","year":"2019","journal-title":"J Nucl Med"},{"key":"R35-6-20241021","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/bjs.4695","article-title":"Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion","volume":"92","author":"Yonemura","year":"2005","journal-title":"Br J Surg"},{"key":"R36-6-20241021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1349-7006.2006.00350.x","article-title":"Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites","volume":"98","author":"Yonemura","year":"2007","journal-title":"Cancer Sci"},{"key":"R37-6-20241021","first-page":"157","article-title":"Advances in the management of gastric cancer with peritoneal dissemination","volume":"169","author":"Yonemura","year":"2007","journal-title":"Recent Results Cancer Res"},{"key":"R38-6-20241021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ags3.12060","article-title":"Treatment of patients with peritoneal metastases from gastric cancer","volume":"2","author":"Kitayama","year":"2018","journal-title":"Ann Gastroenterol Surg"},{"key":"R39-6-20241021","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1158\/1078-0432.CCR-06-1735","article-title":"Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity","volume":"13","author":"Morgan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R40-6-20241021","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4251\/wjgo.v7.i11.285","article-title":"Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes","volume":"7","author":"Yamaguchi","year":"2015","journal-title":"World J Gastrointest Oncol"},{"key":"R41-6-20241021","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"R42-6-20241021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tgh.2016.08.03","article-title":"Intraperitoneal free cancer cells in gastric cancer: Pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy\/hyperthermic intraperitoneal chemotherapy in gastric cancer","volume":"1","author":"Ji","year":"2016","journal-title":"Transl Gastroenterol Hepatol"},{"key":"R43-6-20241021","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/153303460500400407","article-title":"Targeted cancer therapy using radiolabeled monoclonal antibodies","volume":"4","author":"Bethge","year":"2005","journal-title":"Technol Cancer Res Treat"},{"key":"R44-6-20241021","first-page":"92","article-title":"Intracavitary radioimmunotherapy to treat solid tumors","volume":"23","author":"Aarts","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"R45-6-20241021","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1471-2407-10-255","article-title":"The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors","volume":"10","author":"Lee","year":"2010","journal-title":"BMC Cancer"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_124_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:50Z","timestamp":1787067590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_124_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_124_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}